{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:27:32Z","timestamp":1794328052191,"version":"4.9.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL), with \u223c90% of patients cured with frontline treatment. For relapsed or refractory (R\/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor T-cell (CAR T) therapy has been established as the preferred second-line (2L) treatment for primary refractory or early-relapsing LBCL based on the overall survival benefits observed in landmark phase 3 trials. However, patients with PMBCL were underrepresented in these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R\/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage therapy with intent to proceed to high-dose therapy and autologous stem cell transplant (HDT\/ASCT; platinum cohort) and CD19 CAR T therapy (CAR T cohort) were given as 2L therapies in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate, and median progression-free survival (PFS) were significantly higher in the CAR T cohort compared with the platinum cohort (ORR, 91.3% vs 44.2%; P&amp;lt; .001; CR, 65.2% vs 14.7%; P&amp;lt; .001; median PFS, not reached vs 3.5 months; hazard ratio, 0.28; 95% confidence interval, 0.15-0.54; P = .001). No significant difference was observed in overall survival. This study demonstrated the superior response rate and PFS of CD19 CAR T therapy over platinum-based salvage therapy with intent to proceed to HDT\/ASCT as 2L treatment for R\/R PMBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020965","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:58:48Z","timestamp":1787259528000},"page":"7418-7428","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Second-line CD19 CAR T vs platinum salvage and autologous stem cell transplant for primary mediastinal B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9843-3925","authenticated-orcid":false,"given":"Xi","family":"Yang","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2260-8466","authenticated-orcid":false,"given":"Henry","family":"Dumke","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"3City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Argao","sequence":"additional","affiliation":[{"name":"3City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-2537","authenticated-orcid":false,"given":"Joseph G.","family":"Schroers-Martin","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-0667","authenticated-orcid":false,"given":"Sree","family":"Lanka","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":false,"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-084X","authenticated-orcid":false,"given":"Hanan A.","family":"Alharthy","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izel","family":"Okcu","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-5395","authenticated-orcid":false,"given":"Peter G.","family":"Doukas","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, Northwestern Memorial Hospital, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, Northwestern Memorial Hospital, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-4609","authenticated-orcid":false,"given":"Krithika","family":"Shanmugasundaram","sequence":"additional","affiliation":[{"name":"9Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl","family":"Colton","sequence":"additional","affiliation":[{"name":"10Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[{"name":"10Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Marron","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8792","authenticated-orcid":false,"given":"Adam S.","family":"DuVall","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock G.","family":"Lakin","sequence":"additional","affiliation":[{"name":"12Division of Hematology\/Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"12Division of Hematology\/Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1708-3776","authenticated-orcid":false,"given":"Vincenzo J.","family":"Pizzuti","sequence":"additional","affiliation":[{"name":"13Division of Hematology\/Oncology, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"13Division of Hematology\/Oncology, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9362-6622","authenticated-orcid":false,"given":"Olutobi","family":"Adewale","sequence":"additional","affiliation":[{"name":"14Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-9040","authenticated-orcid":false,"given":"Joanna M.","family":"Rhodes","sequence":"additional","affiliation":[{"name":"14Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung","family":"Tiger","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-7322","authenticated-orcid":false,"given":"Kelsey","family":"Baron","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3174-8877","authenticated-orcid":false,"given":"Allison M.","family":"Bock","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-3464","authenticated-orcid":false,"given":"Marcus J.","family":"Geer","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-4448","authenticated-orcid":false,"given":"Yasmin H.","family":"Karimi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,11,2]]},"reference":[{"key":"2026111011013378900_bib1","doi-asserted-by":"crossref","first-page":"115369","DOI":"10.1016\/j.ejca.2025.115369","article-title":"Primary mediastinal B-cell lymphoma (PMBCL): the LYSA pragmatic guidelines","volume":"220","author":"Renaud","year":"2025","journal-title":"Eur J Cancer"},{"issue":"9","key":"2026111011013378900_bib2","first-page":"955","article-title":"Primary mediastinal large B-cell lymphoma","volume":"140","author":"Savage","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"issue":"15","key":"2026111011013378900_bib3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"New Engl J Med"},{"issue":"4","key":"2026111011013378900_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.15051","article-title":"R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis","volume":"180","author":"Shah","year":"2018","journal-title":"Br J Haematol"},{"issue":"suppl 16","key":"2026111011013378900_bib5","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.1200\/JCO.2024.42.16_suppl.7081","article-title":"Outcomes and prognostic factors of patients diagnosed with relapsed\/refractory primary B-cell lymphoma: a retrospective study","volume":"42","author":"Dumke","year":"2024","journal-title":"Am Soc Clin Oncol"},{"issue":"8","key":"2026111011013378900_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41409-017-0063-7","article-title":"Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation","volume":"53","author":"Avivi","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2026111011013378900_bib7","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","article-title":"Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant","volume":"24","author":"Vardhana","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2026111011013378900_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New Engl J Med"},{"issue":"10343","key":"2026111011013378900_bib9","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"The Lancet"},{"issue":"2","key":"2026111011013378900_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"New Engl J Med"},{"issue":"24","key":"2026111011013378900_bib11","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026111011013378900_bib12","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1182\/bloodadvances.2023011203","article-title":"Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA\/DRST registry study","volume":"7","author":"Schubert","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2026111011013378900_bib13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","article-title":"Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study","volume":"38","author":"Chiappella","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2026111011013378900_bib14","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/ajh.70033","article-title":"CD19 CAR T-cell therapy for primary mediastinal large B-cell lymphoma: a CIBMTR analysis","volume":"100","author":"Gauthier","year":"2025","journal-title":"Am J Hematol"},{"issue":"18","key":"2026111011013378900_bib15","first-page":"3563","article-title":"Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma","volume":"5","author":"Crombie","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2026111011013378900_bib16","doi-asserted-by":"crossref","first-page":"e70091","DOI":"10.1002\/hem3.70091","article-title":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry","volume":"9","author":"Galtier","year":"2025","journal-title":"HemaSphere"},{"issue":"27","key":"2026111011013378900_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026111011013378900_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10254","key":"2026111011013378900_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"2026111011013378900_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026111011013378900_bib21","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"2026111011013378900_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2026111011013378900_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2026111011013378900_bib24","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2023-178740","article-title":"Outcomes of patients with primary mediastinal B-cell lymphoma refractory or relapsed after frontline R-EPOCH chemotherapy","volume":"142","author":"Bakos","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026111011013378900_bib25","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1038\/bcj.2015.101","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"5","author":"Aoki","year":"2015","journal-title":"Blood Cancer J"},{"issue":"13","key":"2026111011013378900_bib26","first-page":"2062","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood J Am Soc Hematol"},{"issue":"17","key":"2026111011013378900_bib27","first-page":"3268","article-title":"Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood J Am Soc Hematol"},{"key":"2026111011013378900_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2018-99-110220","article-title":"Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies","volume":"132","author":"Armand","year":"2018","journal-title":"Blood"},{"issue":"33","key":"2026111011013378900_bib29","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/21\/7418\/2598715\/blooda_adv-2026-020965-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/21\/7418\/2598715\/blooda_adv-2026-020965-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:01:40Z","timestamp":1794326500000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/21\/7418\/570339\/Second-line-CD19-CAR-T-vs-platinum-salvage-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,2]]},"references-count":29,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020965","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,10]]},"published":{"date-parts":[[2026,11,2]]}}}